Transplant SIG

Vision

To be the group for collaborative liver transplant research in Canada

Mission

To foster and conduct collaborative research in liver transplantation across Canada

Who we are

The CASL Liver Transplant Interest Group is open to all CASL clinicians and investigators interested in liver transplantation. Interested CASL members should contact the point person at their institution (see below) for further information.

What we do

The CASL Liver Transplant Interest Group meets at least twice a year, typically at CDDW and at AASLD. These meetings serve to

• Review progress/results of ongoing collaborative research projects
• Propose/present new research projects
• Discuss other transplant related issues of common interest

Ongoing Projects

• Efficacy of Sofosbuvir-based antiviral therapy in recurrent hepatitis C after liver transplantation – a pan-Canadian observational study
• Body mass index and outcomes of liver transplantation – a retrospective pan-Canadian analysis

Past Pan-Canadian Projects (examples)

• Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, Bain V, Ghent C, Marotta P, Grant D, Wall W, Tchervenkov J, Barkun J, Roy A, Marleau D, McAlister V, Peltekian K. Liver Transpl. 2003;9:587-95.
• Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS. Liver Transpl. 2005;11:1064-72.
• Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Watt KD, Burak K, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner EL, Yoshida EM; Canadian Transplant Hepatology Outcomes Research Network. Can J Gastroenterol. 2006;20:725-34.
• Survival after liver transplantation for hepatitis C is unchanged over two decades in Canada. Watt KD, Burak KW, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner E, Yoshida EM; Canadian Transplant Hepatology Outcomes Research Network. Can J Gastroenterol. 2008;22:153-4.
• Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Nudo CG, Yoshida EM, Bain VG, Marleau D, Wong P, Marotta PJ, Renner E, Watt KD, Deschênes M. Can J Gastroenterol. 2008;22:821-4.
• Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. Yoshida EM, Lilly LB, Marotta PJ, Mason AL, Bilodeau M, Vaillancourt M. Ann Hepatol. 2013;12:282-93.
• Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, Al-Judaibi B, Renner EL, Lilly Ann Hepatol. 2014;13:525-32.

Point Persons, Institutions, and Contacts

Adult Programs

• Nazia Selzner (Toronto)
• Kevork Peltekian (Dalhousie)
• Marc Bilodeau, (Montreal)
• Philip Wong, (McGill)
• Paul Marotta (Western)
• David Peretz (Manitoba)
• Aldo Montano-Loza (Alberta)
• Stephen Congly (Calgary)
• Eric Yoshida (UBC)

Pediatric Programs

• Fernando Alvarez (Montreal)
• Vicki Ng (SickKids)
• Jason Yap (Alberta)
• Steve Martin (Calgary)

For further information contact the acting secretary of the CASL Transplant Interest group.